Central Plains Eye MDs
Center for Glaucoma, Retina & Diabetic Eye Care
Call Today (316) 712-4970
Patient Portal

Participating in these Active Clinical Trials

Text Size A A A
Enroll in clinical trials

Participation in clinical trials is an indicator of best practice models. Entities funding these important studies do not award trial site status to just any practice. Coordinators for trials apply rigorous evaluation standards to potential investigating physicians and participating sites prior to considering inclusion.

From the patient's perspective, clinical trials provide many benefits. Great attention is directed to those enrolled in a trial, and participation typically incorporates a significant safety net for rescue therapy should a protocol not prove effective clinically. The number of people that may benefit from information learned through clinical trials is untold. Medicine would be hopelessly behind were it not for these physician and patient supported studies.

Retinal Vein Occlusion

A Phase 3, Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA in Combination with an Intravitreal anti-VEGF Agent in Subjects with Retinal Vein Occlusion.

Sponsor: Clearside Biomedical, Inc.
ClinicalTrials.gov Identifier: NCT03203447

Patient must be at least 18 years of age or older and diagnosed with retinal vein occlusion within 6 months of screening and be treatment naïve. Best corrected visual acuity in the study eye between 20/40 and 20/400 using a Snellen chart.

Key Exclusion Criteria: Has in the study eye, used any topical ocular corticosteroid in the 10 days before treatment at Day 0; has at any time received any intraocular or periocular corticosteroid injection. Has a history of any vitreoretinal surgery ever in study eye or any ocular surgery within 3 months before randomization. Prior cataract extraction or YAG laser is allowed but must have been performed at least 3 months prior to baseline. Evidence of or history of any ophthalmic condition in the study eye that may have an associated neovascularization or edema component including, but not limited to, AMD, diabetic retinopathy, diabetic macular edema, retinal detachment, central serous chorioretinopathy, scleritis, optic neuropathy, retinitis pigmentosa, or glaucoma. Have active vitreous hemorrhage in the study eye within the last 90 days. History of MI or CVA within 90 days of treatment.

Enrollment status: Currently Enrolling
For more information on this trial
contact us

Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema

A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection) Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium. Due to the lack of information generated in the pivotal phase III trials assessing potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium, the FDA requested clinical information from a 1-year (minimum) clinical study to support that there are no adverse effects on the corneal endothelium following intravitreal injections of Macugen.

Sponsor: Valeant Pharmaceuticals International, Inc.
ClinicalTrials.gov Identifier: NCT01573572

Patient must be 50 years of age or older and diagnosed with subfoveal neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, or Retinal Vein Occlusion. Best corrected visual acuity in the study eye between 20/20 and 20/400 using a Snellen chart.

Key Exclusion Criteria: Unilateral ocular blunt trauma within one year of enrollment and no greater than 5% difference in central endothelial cell density between the 2 eyes, intraocular surgery (cataract surgery and surgery for glaucoma without tube shunt or mini-shunt) within one year of enrollment, anterior segment laser surgery (laser trabeculoplasty) performed within one year of enrollment, glaucoma tube-shunt surgery, previous history of corneal transplant in the study or non-study eye, presence of vitreous macular traction, previous therapeutic radiation in the region of the study eye, any treatment with an investigational agent in the past 30 days for any condition, severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation.

Enrollment status: Currently Enrolling
For more information on this trial
contact us

Age-Related Macular Degeneration

A Phase 3, Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-1)

Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
ClinicalTrials.gov Identifier: NCT03577899

Patient must be 50 years of age or older and diagnosed with subfoveal or juxtafoveal neovascular Age-Related Macular Degeneration with fluid affecting the fovea on OCT or fluorescein angiogram and have had NO prior ocular treatment or surgery for AMD. Best corrected visual acuity in the study eye between approx. 20/32 and 20/320 using a Snellen chart.

Key Exclusion Criteria: Have a history of intraocular or periocular surgery within 3 months of baseline in the study eye, except in the case of lid surgery then within 1 month of baseline. Have prior pars plana vitrectomy, trabeculectomy or filtration surgery in the study eye. Have clinical evidence of significant diabetic retinopathy that could impact assessment of vision or affect central vision, diabetic macular edema or other vascular disease other than AMD. Have any use of long acting intraocular steroids, including implants, within 6 months prior. Have an allergy to povidone iodine or known serious allergy to the fluorescein sodium for injection in angiography.

Enrollment status: Not Enrolling Yet
For more information on this trial
contact us

Diabetic Macular Edema

A Phase 3, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema (RHINE)

Sponsor: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT03622593

Patient must be 18 years of age or older and diagnosed with diabetes mellitus (Type1 or Type 2), as defined by American Diabetes Association or per WHO criteria and current regular use of insulin or oral anti-hyperglycemic agents and HbA1c of < 10% within 2 months of study visit. Best corrected visual acuity in the study eye between approx. 20/40 and 20/320 using a Snellen chart. Must have evidence of diabetic macular edema involving the center of the fovea.

Key Exclusion Criteria: Have active cancer within the past 12 months except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and possible prostate cancer. Have renal failure requiring renal transplant, hemodialysis or peritoneal dialysis during the study. Have uncontrolled blood pressure. Have history of CVA or MI within 6 months prior to study start. Have uncontrolled glaucoma or high risk proliferative diabetic retinopathy, tractional retinal detachment, epiretinal membrane involving the fovea. Have had focal/grid laser, PRP, or intravitreal anti-VEGF within 3 months prior to study start. Had cataract surgery or YAG laser within 3 months of study start.

Enrollment status: Not Enrolling Yet
For more information on this trial
contact us

Dr. Joe Beck is a caring soul. He and his staff listen to my concerns and patiently answer my many questions. I know I'm getting the most up-to-date and technologically advanced care. I trust Dr. Beck with my eyes. - William R., Judge